Biotechnology stocks have been on quite a roll over the last few weeks, with news of buyouts and mergers driving biotech indices close to all-time highs. The hot roll for biotech continued yesterday, with InterMune Inc (NASDAQ:ITMN) reporting positive Phase III clinical trial results for its drug pirfenidone in patients with idiopathic pulmonary fibrosis. The results showed that pirfenidone significantly reduced IPF disease progression with reference to change in percent predicted forced vital capacity from Baseline to Week 52. Currently available treatments for IPF only offer limited benefits to patients. InterMune Inc (NASDAQ:ITMN) stock opened at $35.69 in last session, and closed at $37.80, while the day range of ITMN stock is $30.20-$38.73.The stock showed a positive weekly performance of 170.77%.
Investors thought highly of Zulily Inc.ZU +0.50% Tuesday, sending the online retailer’s shares up more then 34%, to $56.62, following the company’s first quarterly results since going public in November. Late Monday Zulily, which specializes in short-term sales of goods and clothing for women and children, reported a fourth-quarter profit, excluding one-time items,of 10 cents a share, on revenue of $257 million, compared with earnings of 3 cents a share on $128.5 million in sales in the year-ago period. Wall Street analysts had forecast Zulily to earn 4 cents a share on revenue of $226 million. Zulily Inc (NASDAQ:ZU) stock opened at $51.12, in last session and closed at $58.41, by gained 36.34%.The 52 week range was $34.19-$63.00.Company’s market capitalization is $13.69 billion.
GameStop Corp. (NYSE:GME) is seeing interesting price action, rallying as much as 8.2% at its intraday peak without any significant news to account for the move. With around 60 minutes left in the trading session, the stock has pared its gains ever-so-slightly to 7.4%, at $38.70. GameStop Corp. (NYSE:GME) stock gained 6.71% and finished the last session at $38.47.The EPS of the stock remained 3.38. Company’s market capitalization is $4.46 billion.
Fifth & Pacific Companies (NYSE:FNP) issued its quarterly earnings data on Tuesday. The Fifth & Pacific Companies (NYSE:FNP) reported $0.15 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.30 by $0.15, StockRatingsNetwork reports. The company had revenue of $427.00 million for the quarter, compared to the consensus estimate of $505.76 million. Fifth & Pacific Companies Inc (NYSE:FNP) stock opened the session at $30.96, and closed the session at $35.24.The 52 week range of the FNP stock remained $16.86-$35.31 and the day range was $30.85-$35.31.